E.S.G. Stroes

1.2k citations

22 papers · 888 indexed · h-index 12

Critical Care and Intensive Care Medicine top 2%
Nephrology top 5%
- Chronic Kidney Disease and Diabetes 2
Internal Medicine top 10%
Immunology
- Atherosclerosis and Cardiovascular Diseases 2
Biochemistry top 10%
Surgery
- Lipoproteins and Cardiovascular Health 10
- Cholesterol and Lipid Metabolism 2
Cancer Research
- Cancer, Lipids, and Metabolism 5
Endocrinology, Diabetes and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins 3
Rheumatology
- Systemic Lupus Erythematosus Research 3
- Rheumatoid Arthritis Research and Therapies 3

Co-authors: Hans L. Mooij Max Nieuwdorp Hans Vink Marijn C. Meuwese Bregtje A. Lemkes Reinier O. Schlingemann Hein J. Verberne Lysette N. Broekhuizen
Cited by: Critical Care and Intensive Care Medicine Nephrology Internal Medicine
Journals: Atherosclerosis (3 papers)Journal of clinical lipidology (2 papers)Frontiers in Immunology (1 paper)
Partner nations: Netherlands United States Germany

In The Last Decade

E.S.G. Stroes

21 papers receiving 864 citations

Peers

Countries citing papers authored by E.S.G. Stroes

Since Specialization

Citations

This map shows the geographic impact of E.S.G. Stroes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.S.G. Stroes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.S.G. Stroes more than expected).

Fields of papers citing papers by E.S.G. Stroes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.S.G. Stroes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.S.G. Stroes. The network helps show where E.S.G. Stroes may publish in the future.

Co-authorship network

The 25 scholars most cited alongside E.S.G. Stroes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E.S.G. Stroes Line = papers co-authored together E.S.G. Stroes links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Inhibition of novel lipoprotein(a) receptor major facilitator superfamily domain containing 5 (MFSD5) reduces development of aortic valve calcification Cardiovascular Research ·Francesca Bartoli‐Leonard,Malcolm P. Rogers,吉則井田,栄作渥實,実宮川,Jeff Waterhouse,Mark C. Blaser,I︠u︡. S. Sivopliasov,Calvin Yeang,Erni Mardiati,Chris O’Donnell,Masanori Aikawa,JiWei Huang,E.S.G. Stroes,Elena Aïkawa	2022	1
2	Defective Lipid Droplet–Lysosome Interaction Causes Fatty Liver Disease as Evidenced by Human Mutations in TMEM199 and CCDC115 Cellular and Molecular Gastroenterology and Hepatology ·Lars Emil Larsen,Stanley Amam,Н.И. Сидняев,Jos C. Jansen,Donna Conlon,Volkhard Steude,J.H.M. Levels,Hengyu Song,Vinay Sachdev,Noam Zelcer,Tobias Raabe,Miao He,Nicholas J. Hand,Joost P.H. Drenth,幸枝片岡,E.S.G. Stroes,Dirk J. Lefeber,Johan W. Jonker,Adriaan G. Holleboom	2021	18
3	Improved cardiovascular risk prediction using plasma proteomics in primary prevention Atherosclerosis ·Renate M. Hoogeveen,Doaa Mahmoud,Nick S. Nurmohamed,V. Zampoleri,Michiel J. Bom,Andrea Baragetti,S. Matthijs Boekholdt,Paul Knaapen,Kay‐Tee Khaw,Nicholas J. Wareham,Bart Groen,Alberico L. Catapano,L. Perla,Evgeni Levin,E.S.G. Stroes	2020	1
4	Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides Frontiers in Immunology ·Michel Neidhart,Matti Eskelinen,Katerina Laskari,Niels P. Riksen,Leo A. B. Joosten,Mihai G. Netea,Esther Lutgens,E.S.G. Stroes,Adrian Ciurea,Oliver Distler,Mariam Grigorian,Emmanuel Karouzakis	2019	30
5	Targeting lipoprotein(A)-induced endothelial cell metabolic changes in order to reduce inflammation, leukocyte extravasation and thereby atherosclerosis Atherosclerosis ·Эдуард Олегович Шмит,Renate M. Hoogeveen,Claudia Hagedorn,Miranda Versloot,E.S.G. Stroes,Jeffrey Kroon	2018	1
6	Clinical and Biochemical Features of Different Molecular Etiologies of Familial Chylomicronemia Journal of clinical lipidology ·Robert A. Hegele,Matt Ban,Jian Wang,Andrés Digenio,Veronica J. Alexander,Marcello Arca,Alan G. Jones,Éric Bruckert,E.S.G. Stroes,Jean Bergeron,Fernando Civeira,Joseph L. Witztum,Daniel Gaudet	2017	0
7	ApoA-I Mimetics Handbook of experimental pharmacology ·Robert M. Stoekenbroek,E.S.G. Stroes,G. Kees Hovingh	2014	36
8	Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises. PubMed ·Joost Besseling,G. Kees Hovingh,E.S.G. Stroes	2013	7
9	ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden European Heart Journal ·J. P. Lewis,Diederik F. van Wijk,Adriaan G. Holleboom,Raphaël Duivenvoorden,M. Mahdi Motazacker,Geesje M. Dallinga‐Thie,E. de Groot,John J.P. Kastelein,Aart J. Nederveen,G. Kees Hovingh,E.S.G. Stroes	2012	54
10	Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis Current Pharmaceutical Design ·Radjesh J. Bisoendial,E.S.G. Stroes,Paul P. Tak	2011	17
11	Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus Diabetologia ·Lysette N. Broekhuizen,Bregtje A. Lemkes,Hans L. Mooij,Marijn C. Meuwese,Hein J. Verberne,F. Holleman,Reinier O. Schlingemann,Max Nieuwdorp,E.S.G. Stroes,Hans Vink	2010	317
12	The Prothrombotic State in Rheumatoid Arthritis: An Additive Risk Factor for Adverse Cardiovascular Events Seminars in Thrombosis and Hemostasis ·Radjesh J. Bisoendial,永勲白,Paul‐Peter Tak,E.S.G. Stroes	2010	23
13	P216 CARRIERS OF LCAT GENE MUTATIONS HAVE INCREASED ATHEROSCLEROSIS: A 3.0 TESLA MRI STUDY Atherosclerosis Supplements ·Adriaan G. Holleboom,Raphaël Duivenvoorden,Bas van den Bogaard,E. de Groot,Aart J. Nederveen,Johan S. Laméris,J Kastelein,E.S.G. Stroes,J.A. Kuivenhoven	2010	2
14	Where the immune response meets the vessel wall. PubMed ·Radjesh J. Bisoendial,E.S.G. Stroes,Paul P. Tak	2009	8
15	Tumor necrosis factor-α inhibition protects against endotoxin-induced endothelial glycocalyx perturbation Atherosclerosis ·Max Nieuwdorp,Marijn C. Meuwese,Hans L. Mooij,Miriam H. P. van Lieshout,Anna Hayden,Marcel Levi,Joost C.M. Meijers,Can İnce,John J.P. Kastelein,Hans Vink,E.S.G. Stroes	2008	140
16	Simvastatin with or without ezetimibe in familial hypercholesterolemia (vol 358, pg 1431, 2008) New England Journal of Medicine ·John J.P. Kastelein,Fatima Akdim,E.S.G. Stroes,Aeilko H. Zwinderman,M. L. Bots,A.F.H. Stalenhoef,Frank L.J. Visseren,Eric J.G. Sijbrands,Mieke D. Trip,Evan A. Stein,Daniel Gaudet,Raphaël Duivenvoorden,Enrico P. Veltri,A. David Marais,E. de Groot	2008	10
17	Induction of IRAK-M Is Associated with Lipopolysaccharide Tolerance in a Human Endotoxemia Model The Journal of Immunology ·Cornelis van ′t Veer,Petra S. van den Pangaart,Marieke A. D. van Zoelen,Martijn D. de Kruif,Rakesh S. Birjmohun,E.S.G. Stroes,Alex F. de Vos,Tom van der Poll	2007	143
18	Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients Current Medical Research and Opinion ·Rakesh S. Birjmohun,John J.P. Kastelein,Don Poldermans,E.S.G. Stroes,(unknown),Gerd Assmann	2007	22
19	[The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations]. PubMed ·Rakesh S. Birjmohun,Wim A. van der Steeg,E.S.G. Stroes,J Kastelein	2006	4
20	Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects Kidney International ·Gennady V. Eremin,E.S.G. Stroes,E.A. Muijen,Ton J. Rabelink,Hein A. Koomans,Jaap A. Joles	1999	24

About E.S.G. Stroes

E.S.G. Stroes is a scholar working on Cancer Research, Critical Care and Intensive Care Medicine, Nephrology, Surgery and Rheumatology, having authored 22 papers that have together received 888 indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (10 papers), Cancer, Lipids, and Metabolism (5 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (3 papers), Systemic Lupus Erythematosus Research (3 papers), Rheumatoid Arthritis Research and Therapies (3 papers), Chronic Kidney Disease and Diabetes (2 papers), Atherosclerosis and Cardiovascular Diseases (2 papers) and Cholesterol and Lipid Metabolism (2 papers). The work is most often cited by research in Critical Care and Intensive Care Medicine (226 citations), Nephrology (118 citations), Internal Medicine (36 citations), Immunology (199 citations) and Biochemistry (51 citations). E.S.G. Stroes has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Hans L. Mooij, Max Nieuwdorp, Hans Vink, Marijn C. Meuwese, Bregtje A. Lemkes, Reinier O. Schlingemann, Hein J. Verberne, Lysette N. Broekhuizen, F. Holleman and Rakesh S. Birjmohun. Their work appears in journals such as Atherosclerosis, Journal of clinical lipidology, Frontiers in Immunology, Cardiovascular Research and Atherosclerosis Supplements.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact